Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 5 PART I, 1998, Pages 1432-1441

  Meduri, G Umberto ^a   Tolley, Elizabeth A ^a   Chinn, Albert ^a   Stentz, Frankie ^a   Postlethwaite, Arnold ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; COLLAGEN TYPE 1; CREATININE; METHYLPREDNISOLONE; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG LAVAGE; MALE; ORAL DRUG ADMINISTRATION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; SCORING SYSTEM;

ADULT; ANTI-INFLAMMATORY AGENTS; BILIRUBIN; BIOLOGICAL MARKERS; BODY TEMPERATURE; BRONCHOALVEOLAR LAVAGE FLUID; CREATININE; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MUCINS; MULTIPLE ORGAN FAILURE; OXYGEN; PEPTIDE FRAGMENTS; PLACEBOS; POSITIVE-PRESSURE RESPIRATION; PROCOLLAGEN; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031790603     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.5.9801107     Document Type: Article

References (47)

1. Meduri, G. U. 1996. The role of the host defense response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur. Respir. J. 9:2650-2670.
2. Stricter, R. M., N. W. Lukacs, T. J. Standiford, and S. L. Kunkel. 1993. Cytokines and lung inflammation: mechanisms of neutrophil recruitment to the lung. Thorax 48:765-769.
3. Van Der Poll, T., H. R. Buller, H. T. Cate, C. H. Wortel, K. A. Bauer, S. J. K. VanDeventer, C. E. Hack, H. P. Sauerwein, R. D. Rosenberg, and J. W. Cate. 1990. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 322:1622-1627.
4. Elias, J. A., B. Freundlich, J. A. Kern, and J. Rosenbloom. 1990. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 97:1439-1445.
5. King, R. J., M. B. Jones, and P. Minoo. 1989. Regulation of lung cell proliferation by polypeptide growth factors. Am. J. Physiol. 257:L23-L38.
6. Postlethwaite, A. E., and J. M. Seyer. 1990. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor α (TNF-α) and a synthetic TNF-α 31-68 peptide. J. Exp. Med. 172:1749-1756.
7. Horslev-Petersen, K. 1990. Circulating extracellular matrix components as markers for connective tissue response to inflammation. Danish Medical Bulletin 37:308-329.
8. Kovacs, E. J., and L. A. Dipietro. 1994. Fibrogenic cytokines and connective tissue production. FASEB J. 8:854-861.
9. Bitterman, P. B., and C. A. Henke. 1991. Fibroproliferative disorders. Chest 99:81S-84S.
10. Meduri, G. U., S. Headley, G. Kohler, F. Stentz, E. Tolley, R. Umberger, and K. Leeper. 1995. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-β and IL-6 are consistent and efficient predictors of outcome over time. Chest 107:1062-1073.
11. Meduri, G. U., G. Kohler, S. Headley, E. Tolley, F. Stentz, and A. Postlethwaite. 1995. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest 108:1303-1314.
12. Meduri, G. U., M. ElTorky, and H. T. Winer-Muram. 1995. The fibroproliferative phase of late adult respiratory distress syndrome. Semin. Respir. Infect. 10:154-175.
13. Postlethwaite, A. E. 1995. Role of T cells and cytokines in effecting fibrosis. Intern. Rev. Immunol. 12:247-258.
14. Fessler, J. H., and L. I. Fessier. 1978. Biosynthesis of procollagen. Ann. Rev. Biochem. 47:129-162.
15. Kessler, E., and B. Goldberg. 1978. A method for assaying the activity of the endopeptidases which excises the nonhelical carboxyterminal extensions from type I procollagen. Anal. Biochem. 86:463-469.
16. Kirk, J. E., E. D. Bateman, P. Haslam, G. J. Laurent, and M. Turner-Warwick. 1984. Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance. Thorax 39: 726-732.
17. Entzian, P., A. Huckstadt, H. Kreipe, and J. Barth. 1990. Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients: pronounced augmented concentrations in the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 142:1079-1082.
18. 2 removal. Eur. J. Clin. Chem. Clin. Biochem. 29:805-812.
19. Waydhas, C., D. Nast-Kolb, A. Trupka, S. Lenk, K. H. Duswald, L. Schweiberer, and M. Jochum. 1993. Increased serum concentrations of procollagen type III peptide in severely injured patients: an indicator of fibrosing activity? Crit. Care Med. 21:240-247.
20. Clark, J. G., J. A. Milberg, K. P. Steinberg, and L. D. Hudson. 1995. Type III procollagen peptide in the adult respiratory distress syn drome: association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann. Intern. Med. 122:17-23.
21. Durant, S., D. Duval, and F. Homo-Delarche. 1986. Factors involved in the control of fibroblast proliferation by glucocorticoids: a review. Endocr. Rev. 7:254-268.
22. Meduri, G. U., J. M. Belenchia, R. J. Estes, R. G. Wunderink, M. ElTorky, and K. V. Leeper, Jr. 1991. Fibroproliferative phase of ARDS: clinical findings and effects of corticosteroids. Chest 100:943-952.
23. Murray, J. F., M. A. Matthay, J. M. Luce, and M. R. Flick. 1988. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138:720-723.
24. Bernard, G. R., G. Doig, L. D. Hudson, S. Lemeshow, J. C. Marshall, J. Russell, W. Sibbald, C. L. Sprung, J. L. Vincent, A. P. Wheeler, and Ad Hoc Committees for Organ Failure. 1995. Quantification of organ failure for clinical trials (abstract). Am. J. Respir. Crit. Care Med. 151: A323.
25. Meduri, G. U., A. S. Headley, E. Golden, S. J. Carson, R. A. Umberger, T. Kelso, and E. A. Tolley. 1998. Prolonged methylprednisolone treatment improves lung function and outcome in patients with unresolving acute respiratory distress syndrome: results of a randomized, double-blind, placebo-controlled trial. J.A.M.A. 280:159-165.
26. Bernard, G. R., A. Artigas, K. L. Brigham, J. Carlet, K. Falke, L. Hudson, M. Lamy, J. R. Legall, A. Morris, R. Spragg, and the Consensus Committee. 1994. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am. J. Respir. Crit. Care Med. 149:818-824.
27. Slutsky, A. S. 1993. Mechanical ventilation. Chest 104:1833-1059.
28. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. H. Schein, and W. J. Sibbald. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644-1655.
29. Meduri, G. U., G. L. Mauldin, R. G. Wunderink, K. V. Leeper, C. B. Jones, E. Tolley, and G. Mayhall. 1994. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 106:221-235.
30. Meduri, G. U., and J. Chastre. 1992. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest 102:557S-564S.
31. Sokal, R. R., and F. J. Rohlf. 1981. Biometry: The Principles and Practice of Statistics in Biological Research, 2nd ed. W. H. Freeman and Co., New York. 215-216.
32. Chesnut, A. N., M. A. Matthay, and J. G. Clark. 1996. Type III procollagen peptide is present in pulmonary edema fluid on day one in patients with acute respiratory distress syndrome (ARDS) (abstract). Am. J. Respir. Crit. Care Med. 153:A11.
33. Deheinzelin, D., F. B. Jatene, P. H. N. Saldiva, and R. R. Brentani. 1997. Upregulation of collagen messenger RNA expression occurs immediately after lung damage. Chest 112:1184-1188.
34. Fukuda, Y., M. Ishizaki, Y. Masuda, G. Kimura, O. Kawanami, and Y. Masugi. 1987. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar dam-age. Am. J. Pathol. 126:171-182.
35. Bernard, G. R., J. M. Luce, C. L. Sprung, J. E. Rinaldo, R. M. Tate, W. J. Sibbald, K. Kariman, S. Higgins, R. Bradley, C. A. Metz, T. R. Harris, and K. L. Brigham. 1987. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med. 317:1565-1570.
36. O2 and its response to conventional therapy. Chest 96:849-851.
37. Headley, A. S., E. Tolley, and G. U. Meduri. 1997. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 111:1306-1321.
38. Meduri, G. U. 1997. Host defense response and outcome in ARDS. Chest 112:1154-1158.
39. Farjanel, J., D. J. Hartmann, B. Guidet, L. Luquel, and G. Offenstadt. 1993. Four markers of collagen metabolism as possible indicators of disease in the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 147:1091-1099.
40. Low, R. B., M. S. Giancola, T. E. King, J. Chapitis, P. Vacek, and G. S. Davis. 1992. Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 146:701-706.
41. Krane, S. M. 1984. Genetic and acquired disorders of collagen deposition. In K. A. Piez and A. H. Reddi, editors. Extracellular Matrix Biochemistry. Elsevier, New York. 413-463.
42. Abe, S., B. U. Steinmann, L. M. Wahl, and G. R. Martin. 1979. High cell density alters the ratio of type III to type I collagen synthesis by fibroblasts. Nature 279:442-444.
43. Kelley, J., L. Trombley, E. J. Kovacs, G. S. Davis, and M. Absher. 1981. Pulmonary macrophages alter the collagen phenotype of lung fibroblasts. J. Cell. Physiol. 109:353-361.
44. Bentsen, K. D., T. L. Nielsen, J. K. M. Eaftinck Schattenkerk, B. N. Jensen, J. D. Lundgren, and the Copenhagen-Amsterdam PCP-prednisolone Study Group. 1993. Serum type III procollagen peptide in patients with Pneumocystis carinii infection. Am. Rev. Respir. Dis. 148:1558-1562.
45. Meduri, G. U., A. J. Chinn, K. V. Leeper, R. G. Wunderink, E. Tolley, H. T. Winer-Muram, V. Khare, and M. EITorky. 1994. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: patterns of response and predictors of outcome. Chest 105:1516-1527.
46. Meduri, G. U., S. Headley, E. Tolley, M. Shelby, F. Stentz, and A. Postlethwaite. 1995. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 108:1315-1325.
47. Knaus, W. A., D. P. Wagner, E. A. Draper, J. E. Zimmerman, M. Bergner, P. G. Bastos, C. A. Sirio, D. J. Murphy, T. Lotring, A. Damiano, and F. E. Harrell. 1991. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100:1619-1636.